Step 1: Trace metformin's core mechanism, lowering insulin resistance, and see which listed conditions share that pathophysiology.
Step 2: In type 2 diabetes it curbs liver glucose output and improves peripheral glucose handling, making it the first line agent. That secures option (a).
Step 3: Polycystic ovarian disease is driven by insulin resistance and compensatory high insulin, which disturbs ovarian function. By easing that resistance, metformin helps restore cycles and ovulation, so option (b) is equally valid.
Step 4: Pregnancy induced hypertension is managed with antihypertensives such as labetalol or methyldopa, not metformin, so (c) does not fit. With two correct indications established, the inclusive choice is the answer.
\[\boxed{\text{Both diabetes and PCOD}}\]